ibrutinib treatment for cll does not increase the incidence of richter’s transformation
Published 4 months ago • 107 plays • Length 2:38Download video MP4
Download video MP3
Similar videos
-
1:46
acalabrutinib for the treatment of richter's transformation and patients with ibrutinib intolerance
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
1:54
nivolumab ibrutinib for patients with richter’s transformation
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
3:48
ibrutinib in treatment for refractory or relapsed cll
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
10:14
cll: the risk of richter’s transformation
-
2:14
ibrutinib's role in cll treatment and future outlooks
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
1:26
treating richter’s transformation with venetoclax, obinutuzumab and atezolizumab
-
1:09
ibrutinib combination therapy in cll: overview of the data so far
-
2:17
epcore cll-1: epcoritamab in patients with r/r cll & richter's transformation
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
1:15
the role of transplant in cll and richter's transformation today
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
1:01
next steps for the use of ibrutinib and venetoclax for the treatment of lymphoma
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll